A phase 1 dose-escalation/expansion study (NCT03260491) confirmed the safety and efficacy of HER3-DXd in patients with EGFR-mutated NSCLC with prior EGFR TKI therapy [178]. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.